EN DE
Watch Broncus Holding Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Broncus Holding Corp (2216) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Broncus Holding Corp stock HK$0.29, price HK$0.54, that is 47.0% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG1609T1022

BH Broncus Holding Corp logo Thin data Nov 10, 2026

Broncus Holding Corp

2216 · HK

Far too expensive (fair value 47% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +99% vs. a year ago. 
Mixed vs. peers (3/7) 
Fair value HK$0.2862 · Strongly overvalued 
Quality 39/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −44.3 %/yr in CNY) 
Negative free cash flow 
Narrow moat 9/100
Thin data 
Estimate
Watch Broncus Holding Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$15.10 HK$0.4600 Fair Value HK$0.2862 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.4600 – HK$15.10 · fair‑value band HK$0.2147 – HK$0.3578 · the HK$0.5400 price screens above the HK$0.2862 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Broncus Holding in your weekly email

Every Wednesday you see whether Broncus Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally.

Show moreShow less

The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; BroncTarget Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of acute COPD exacerbation management; H-Marker, a pulmonary surgical marker that can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, thoracic surgery staining location, etc.; and BroncTru, a disposable transbronchoscopic dilatation catheter.

It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system.

In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath, and for used to dilate the target lung tissue of the bronchial tree; BioStarNeedle, a single use ultrasound-guided needle for retrieval of tissue samples; and Steerable Sheath, a steerable sheath adjustment handle and a working channel.

The company was incorporated in 2012 and is headquartered in Hangzhou, China.

Stock analysis

Broncus Holding Corp (2216) currently trades at HK$0.5400, while our estimate is HK$0.2862, 47% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.2147 (bear) to HK$0.3578 (bull), the price of HK$0.5400 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Broncus Holding Corp reported revenue of 174K CNY in FY2025 versus 10.9M CNY in FY2021, a compound −64.4%/yr. Reported net income was −17.9M CNY in FY2025.

Key figures

Market cap HK$285M (≈ $36.3M) Micro · Return on equity −12.0% · Return on assets (EBIT) −15.2% (5-year average) · Operating margin −300% · Revenue growth (YoY) +99.0% · Free cash flow −10.0M CNY · Net cash 31.9M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 80% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −47%, 2216 screens richer than that median.

Fair Value

Bear HK$0.2147 Fair Value HK$0.2862 Bull HK$0.3578
Price HK$0.5400 · Downside -47.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−97.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−73.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−44.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−47.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−648.5% (2020) → −14,017.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2216 screens overvalued: fair value 47% below the price. Compare with Abbott Laboratories, →

Compare Broncus Holding Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −47.0% · Bottom 25%
Profitability
Return on assets −11.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 99.0% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.61× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 41
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $343.63 +11% vs 2216
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs 2216
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs 2216
DexCom, Inc DXCM $83.33 $91.66 +10% vs 2216
STERIS plc STE $264.32 $281.90 +7% vs 2216
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs 2216
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs 2216
Medtronic plc MDT $102.86 $74.90 −27% vs 2216
Abbott Laboratories, ABT $108.52 $75.28 −31% vs 2216
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs 2216

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Broncus Holding Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Broncus Holding Corp Fair Value". https://www.fairvalue-calculator.com/stock/2216

Frequently asked questions

Is Broncus Holding Corp (2216) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.2862 versus a price of HK$0.5400, about 47% lower (overvalued).
What is the fair value of 2216?
Our estimate for Broncus Holding Corp is HK$0.2862 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.5400.
What is the quality score of 2216?
Broncus Holding Corp has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Broncus Holding Corp (2216)?
Our calculated price target is the estimate of HK$0.2862 (as of Nov 10, 2026). Cautious scenario HK$0.2147, optimistic scenario HK$0.3578. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Broncus Holding Corp stock forecast for 2026?
Our estimate puts fair value at HK$0.2862, about 47% lower versus a price of HK$0.5400 (overvalued). Cautious scenario HK$0.2147, optimistic scenario HK$0.3578. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Broncus Holding Corp (2216)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Broncus Holding Corp it is HK$0.2862 per share (as of Nov 10, 2026), against a price of HK$0.5400.
Is Broncus Holding Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2216 trades above its calculated fair value: price HK$0.5400, fair value HK$0.2862, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2216?
No. The price is what the market pays today (HK$0.5400); the fair value is what the company's own numbers justify (HK$0.2862). For Broncus Holding Corp the two are HK$0.2538 per share apart. That gap is exactly why we show both numbers side by side.
How much is Broncus Holding Corp worth?
The market values Broncus Holding Corp at about HK$285M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.5400; our models calculate a fair value of HK$0.2862 per share.
What do the bullish and bearish scenarios say about 2216?
Our models span a range for Broncus Holding Corp: cautious scenario HK$0.2147, base HK$0.2862, optimistic HK$0.3578 per share (as of Nov 10, 2026, price HK$0.5400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Broncus Holding Corp (2216)?
Balance-sheet figures for Broncus Holding Corp (as of Nov 10, 2026): return on equity −12.0%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 2216 from its 52-week high?
Broncus Holding Corp trades at HK$0.5400, about 80% below its 52-week high of HK$2.74 and 1% above the low of HK$0.5350 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.2862 is for.
Which stocks are comparable to Broncus Holding Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Broncus Holding Corp stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.5400, calculated fair value HK$0.2862 (−47%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Broncus Holding Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Broncus Holding Corp (2216)?
The closing price on Nov 13, 2026 was HK$0.5400. Our estimate is HK$0.2862, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Broncus Holding Corp right now?
The price sits above even our optimistic bull case (HK$0.3578). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Broncus Holding Corp

How large is the market capitalisation of Broncus Holding Corp (2216)?
The market capitalisation of Broncus Holding Corp is HK$285M (≈ $36.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of Broncus Holding Corp (2216)?
The return on equity (ROE) of Broncus Holding Corp is −12.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Broncus Holding Corp (2216)?
On an EBIT basis the return on assets of Broncus Holding Corp is −15.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Broncus Holding Corp (2216)?
The operating margin of Broncus Holding Corp is −300% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Broncus Holding Corp (2216)?
Revenue at Broncus Holding Corp is growing 99.0% versus a year earlier (3y avg −73.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Broncus Holding Corp (2216) generate?
The free cash flow of Broncus Holding Corp is −10.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Broncus Holding Corp (2216) hold?
Broncus Holding Corp holds more cash than debt, 31.9M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Broncus Holding Corp in the live analysis

One click puts Broncus Holding Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.